Protocol Ledger

NCT06033131 · Phase III · RECRUITING

PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia

Interventional Phase III clinical trial protocol NCT06033131 sponsored by Lina Bergman in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-19 Enrollment: 294 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06033131
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)294 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06033131
Protocol FieldVerified Registry Value
NCT IdentifierNCT06033131
Consolidated Lead SponsorLina Bergman
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment294 participants (ESTIMATED)
Registered Start Date2024-01-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06033131
Hospital Research SiteLocationSite Profile
Tampere University HospitalTampere, FinlandOpen Hospital Dossier ->
Oslo University HospitalOslo, NorwayOpen Hospital Dossier ->
Sahlgrenska University hospitalGothenburg, SwedenOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI